171 related articles for article (PubMed ID: 27057662)
1. Are chimeric antigen receptor T cells ready for prime time?
Brentjens RJ
Clin Adv Hematol Oncol; 2016 Jan; 14(1):17-9. PubMed ID: 27057662
[No Abstract] [Full Text] [Related]
2. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
3. Perspective: assembly line immunotherapy.
Levine BL; June CH
Nature; 2013 Jun; 498(7455):S17. PubMed ID: 23803946
[No Abstract] [Full Text] [Related]
4. Advances in CAR T-cell therapy for chronic lymphocytic leukemia.
Porter DL
Clin Adv Hematol Oncol; 2018 Feb; 16(2):118-120. PubMed ID: 29741512
[No Abstract] [Full Text] [Related]
5. CAR T-cells merge into the fast lane of cancer care.
Frey NV; Porter DL
Am J Hematol; 2016 Jan; 91(1):146-50. PubMed ID: 26574400
[TBL] [Abstract][Full Text] [Related]
6. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
7. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
Hill JA; Li D; Hay KA; Green ML; Cherian S; Chen X; Riddell SR; Maloney DG; Boeckh M; Turtle CJ
Blood; 2018 Jan; 131(1):121-130. PubMed ID: 29038338
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.
Brower V
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25838441
[No Abstract] [Full Text] [Related]
9. CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.
Quintás-Cardama A
Leuk Lymphoma; 2019 May; 60(5):1346-1348. PubMed ID: 30646790
[No Abstract] [Full Text] [Related]
10. Transcription Activator-Like Nucleases Enable Allogeneic Chimeric Antigen Receptor-T Cell Therapy in Humans.
Flotte TR
Hum Gene Ther; 2015 Nov; 26(11):iv. PubMed ID: 26565678
[No Abstract] [Full Text] [Related]
11. Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.
Zheng S; Asnani M; Thomas-Tikhonenko A
Cancer J; 2019; 25(3):217-222. PubMed ID: 31135529
[TBL] [Abstract][Full Text] [Related]
12. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.
Shah N; Rezvani K; Hosing C; Kebriaei P; Wierda W; Cooper L; Shpall E
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl(Suppl):S18-22. PubMed ID: 25486950
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
Sikaria S; Aldoss I; Akhtari M
Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
[TBL] [Abstract][Full Text] [Related]
14. Genetic engineering of T cells in leukemia and lymphoma.
Kochenderfer JN
Clin Adv Hematol Oncol; 2014 Mar; 12(3):190-2. PubMed ID: 24927269
[No Abstract] [Full Text] [Related]
15. The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors.
DeRenzo C; Krenciute G; Gottschalk S
Am Soc Clin Oncol Educ Book; 2018 May; 38():830-837. PubMed ID: 30231350
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.
Jahn L; Hombrink P; Hassan C; Kester MG; van der Steen DM; Hagedoorn RS; Falkenburg JH; van Veelen PA; Heemskerk MH
Blood; 2015 Feb; 125(6):949-58. PubMed ID: 25414443
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia: Are We Any Closer to a Cure?
Rhodes JM; Schuster SJ
Cancer J; 2019; 25(6):436-441. PubMed ID: 31764125
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.
Mato AR; Thompson MC; Nabhan C; Svoboda J; Schuster SJ
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):852-856. PubMed ID: 28826693
[TBL] [Abstract][Full Text] [Related]
19. T-Cell Therapy Has Lasting Effects.
Cancer Discov; 2016 Feb; 6(2):113. PubMed ID: 26719386
[TBL] [Abstract][Full Text] [Related]
20. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
